Legislation to create and fund a pilot program for the medical use of psilocybin mushrooms was recently filed in the Wisconsin Legislature.
Dried psilocybin mushrooms. (Photo credit: Rich Townsend/Getty Images)
House Bill 753 was filed last month by State Representative Nate Gustafson along with a bipartisan coalition of 23 cosponsors, and assigned to the House Committee on Health, Aging and Long-Term Care. Today the measure received an official fiscal note.
The measure would create “a medicinal psilocybin treatment fund and a pilot program to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome at the University of Wisconsin-Madison and making an appropriation.”
The measure would “create a new nonlapsible trust fund managed by the State of Wisconsin Investment Board designated as the medicinal psilocybin treatment fund and a $100,000 appropriation in 2023-24 for the UW System.”
The funding would be used “to create a medicinal psilocybin treatment pilot program at UW-Madison to study the effects of medicinal psilocybin treatment on patients with post-traumatic stress syndrome (PTSD).”
Within 6 months of the completion of the pilot program a report would need to be submitted to the governor and appropriate committees “of the legislature detailing the results of the pilot program and any recommendations for legislation based on the pilot program’s results.”
